Videos

Understanding MDS risk classification enhances patient care, focusing on tailored therapies and improving quality of life through effective treatment strategies.

Dr Robert Orlowski highlights strategies to prevent infections in patients with multiple myeloma treated with linvoseltamab, emphasizing antiviral prophylaxis and IVIG use.

Fadi Haddad, MD, discusses the use of asciminib in patients with chronic myeloid leukemia.

Explore the significance of MRD negativity in cancer prognosis and its implications for treatment strategies in community-based practices.

A recent study highlights asciminib's effectiveness in treating newly diagnosed CML, showing promising molecular response rates and safety profiles.

Martin F. Dietrich, MD, discusses the use of the CDK4/6 inhibitor trilaciclib to address myelosuppression associated with chemotherapy in small cell lung cancer.

A phase 2 study reveals promising efficacy and safety of TKI and inotuzumab ozogamicin therapy for newly diagnosed Ph+ ALL, achieving high response rates.

Researchers explore the safety and efficacy of consolidating cevostamab with BCMA CAR T therapy for relapsed multiple myeloma, highlighting management protocols.

Panelists discuss how emerging targeted agents are poised to reshape the therapeutic landscape for EGFR-mutant NSCLC in the coming years.

Panelists discuss how proactive sequencing strategies optimize long-term outcomes in EGFR-mutant non–small-cell lung cancer (NSCLC) by anticipating resistance patterns.

Panelists discuss how patient-centered counseling and shared decision-making shape personalized treatment journeys in EGFR-mutant non–small-cell lung cancer (NSCLC).

Panelists discuss how adherence to guidelines and vigilant imaging support optimal management of CNS disease in EGFR-mutant non–small-cell lung cancer.

Panelists discuss how real-world practice blends evidence-based guidance with individualized adjustments for high-risk EGFR-mutant non–small-cell lung cancer (NSCLC) cases.

Discover how a remote therapeutic monitoring system enhances patient care and streamlines clinic operations, reducing hospitalizations for hematologic malignancies.

Remote therapeutic monitoring significantly lowers infection-related hospitalizations in hematological cancer patients, enhancing outpatient care and reducing emergency visits.

Outpatient CAR T-cell therapy shows promising efficacy and manageable safety in treating relapsed multiple myeloma, with high response rates and minimal long-term toxicity.

Discover the nuances of CAR T-cell therapy eligibility and its advantages over traditional chemotherapy for long-term patient outcomes.

Long-term follow-up of the TRANSFORM study reveals liso-cel's impressive efficacy and safety in treating relapsed large B-cell lymphoma.

Comprehensive biomarker testing at the time of early NSCLC diagnosis is critical because it ensures that clinicians identify actionable molecular alterations before definitive treatment plans are set.

Panelists discuss how trial data and practical considerations inform the nuanced choice between amivantamab–lazertinib and osimertinib in managing EGFR-mutant non–small-cell lung cancer (NSCLC) with CNS disease.

Panelists discuss how personalized molecular insights drive first-line therapy choices in EGFR-mutant NSCLC with complex metastatic profiles.

Comprehensive biomarker testing in early-stage NSCLC requires coordination across multiple specialties, including thoracic surgery, medical oncology, pathology, pulmonology, and radiology.

The ACCESS study reveals that posttransplant cyclophosphamide improves survival rates for patients with mismatched unrelated donor transplants, expanding donor options.

Heather Stefanski, MD, PhD, discusses the unmet needs for patients undergoing bone marrow and stem cell transplants.

Peter Voorhees, MD, discusses the evolving treatment landscape for smoldering multiple myeloma, highlighting new therapies and clinical trial opportunities.

Dr. Peter Voorhees discusses risk stratification in smoldering multiple myeloma, highlighting the IMWG criteria and the benefits of daratumumab treatment.

Peter Voorhees, MD, discusses groundbreaking AQUILA study results, highlighting daratumumab's significant impact on high-risk smoldering multiple myeloma treatment.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.

Che-Kai Tsao, MD, MS, discusses new approaches that could change the standard of care for metastatic hormone-sensitive prostate cancer.

Peter Voorhees, MD, discusses the AQUILA study's impact on treating patients with high-risk smoldering multiple myeloma, paving the way for new therapies.